Stay updated with breaking news from Refractory Multiple. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- 100% ORR at both dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 22 of 31 (71%) evaluable patients reached...
-- 100% ORR at both dose levels; deep and durable responses observed in patients with poor prognostic factors ---- 22 of 31 (71%) evaluable patien...
CARVYKTI is Legend Biotech's first European Commission-approved product The approval is based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR)
In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients
Longer term follow-up data will be presented from the pivotal CARTITUDE-1 study in patients with relapsed or refractory multiple myeloma, which supported the recent U.S. FDA approval of CARVYKTI